<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04183608</url>
  </required_header>
  <id_info>
    <org_study_id>GETAID-2018-01</org_study_id>
    <nct_id>NCT04183608</nct_id>
  </id_info>
  <brief_title>A Trial COmparing staNdard of Care Versus Treat to Target With telemonitoRing and Patient Education in Patients With Ulcerative cOlitis Initiating Adalimumab</brief_title>
  <acronym>CONTROL</acronym>
  <official_title>An Open-label Randomized Trial COmparing staNdard of Care Versus Treat to Target With telemonitoRing and Patient Education in Patients With Ulcerative cOlitis Initiating adaLimumab: The CONTROL Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      PHASE: IV&#xD;
&#xD;
      DESCRIPTIVE: Randomized, interventional, open label multicenter trial&#xD;
&#xD;
      POPULATION: Moderate to severe ulcerative colitis&#xD;
&#xD;
      STUDY TREATMENTS: Patients will all receive Adalimumab 160/80/40mg EOW until V1 (W14)&#xD;
      followed by 40mg EOW until V2 (W26) and could be optimized up to 80mg EOW (or 40 EW according&#xD;
      to patient and/or investigator preference) for two months and then could be optimized up to&#xD;
      80mg EOW (or 40 EW according to patient and/or investigator preference) and azathioprine&#xD;
      (2.0/2.5 mg/kg/ day) or methotrexate (25 mg EW) until V3 (W 38).&#xD;
&#xD;
      OBJECTIVES: To assess the impact of a treat to target treatment follow up by e-Monitoring and&#xD;
      fecal calprotectin dosing at home associated to an appropriate patient education versus&#xD;
      standard treatment follow up at W48 in patients requiring a treatment with adalimumab&#xD;
      (Humira®).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      NUMBER OF PATIENTS : 238 patients in 20 sites in France&#xD;
&#xD;
      RECRUITMENT PERIOD : The trial duration for each patient will be 144 weeks&#xD;
&#xD;
      MAIN ENDPOINT : At week 48 success defined by: Endoscopic remission defined by an endoscopic&#xD;
      Mayo score 0&#xD;
&#xD;
      SECONDARY ENDPOINTS:&#xD;
&#xD;
      At W48&#xD;
&#xD;
        -  Clinical remission (Clinical remission is defined as a total Mayo score ≤2 points, with&#xD;
           no individual sub score &gt;1, and a Mayo endoscopy sub score of 0 or 1)&#xD;
&#xD;
        -  Remission without steroids&#xD;
&#xD;
        -  Endoscopic healing rate with Mayo score 0 or 1&#xD;
&#xD;
        -  UCEIS score&#xD;
&#xD;
        -  Histological healing (Nancy score)&#xD;
&#xD;
        -  Remission rate and remission rate without steroids at study visits and W48&#xD;
&#xD;
        -  Quality of life evolution (evaluate visit W0 vs W14, W26, W38 and W48)&#xD;
&#xD;
        -  Patients satisfaction&#xD;
&#xD;
        -  Continuous response&#xD;
&#xD;
        -  Safety and tolerability&#xD;
&#xD;
        -  Anti-TNF pharmacokinetics&#xD;
&#xD;
        -  Number of visits in trial&#xD;
&#xD;
        -  Number of UC related hospitalizations&#xD;
&#xD;
        -  Number of colectomies&#xD;
&#xD;
        -  Treatment compliance (questionnaire)&#xD;
&#xD;
        -  Patient adhesion (questionnaire)&#xD;
&#xD;
        -  Medico-economic analysis&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 14, 2020</start_date>
  <completion_date type="Anticipated">May 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endoscopic Remission</measure>
    <time_frame>Week 48</time_frame>
    <description>Treatment success of a treat to target with telemonitoring follow up using e-Monitoring and fecal calprotectin dosing at home associated to an appropriate patient education compared to standard treatment follow up at Week 48.&#xD;
Definition of treatment success: Endoscopic remission defined by an endoscopic Mayo score 0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of adalimumab treatment on clinical remission (at Week 48)</measure>
    <time_frame>Week 48</time_frame>
    <description>Remission without steroids:&#xD;
Remission rate and remission rate without steroids at study visits and Week 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of adalimumab treatment on endoscopic Healing (at Week 48)</measure>
    <time_frame>Week 48</time_frame>
    <description>Endoscopic healing rate with Mayo score 0 or 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of adalimumab treatment on endoscopic mucosal healing</measure>
    <time_frame>Week 48</time_frame>
    <description>UCEIS score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of adalimumab treatment on histological Healing (at Week 48)</measure>
    <time_frame>Week 48</time_frame>
    <description>Histological healing (Nancy index)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of adalimumab treatment on patient quality of life (at Week 48)</measure>
    <time_frame>Week 48</time_frame>
    <description>Quality of life evolution (evaluate visit 0 vs -Week 14, Week 26, Week 38 and Week 48)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction</measure>
    <time_frame>Week 48</time_frame>
    <description>Patient satisfaction evaluate with all questionnaires of quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment compliance</measure>
    <time_frame>Week 48</time_frame>
    <description>Treatment compliance evaluate at every visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient adhesion</measure>
    <time_frame>Week 48</time_frame>
    <description>Patient adhesion evaluate with questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disability score evolution</measure>
    <time_frame>Week 48</time_frame>
    <description>IBD Disability index, evaluate visit 0 vs - Week 14, Week 26, Week 38 and Week 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medico-economic analysis</measure>
    <time_frame>Week 48</time_frame>
    <description>Medico-economic comparative analysis between standard of care follow up and tight monitoring follow up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Continuous Clinical Response (CCR)</measure>
    <time_frame>Week 48</time_frame>
    <description>Definition: Partial Mayo Response at each visit (Visit 1, Visit 2, Visit 3) with a total Mayo response on Week 48 Visit 4 visit. In the telemonitoring group the partial Mayo limited to questions 1 and 2 will be directly answered by patients themselves through ePRO2 they will score the first 2 questions of partial Mayo from home and send that info to the investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Loss of clinical response</measure>
    <time_frame>Week 48</time_frame>
    <description>Pharmacokinetic dosage of Adalimumab (Anti-TNF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of visits in trial</measure>
    <time_frame>Week 48</time_frame>
    <description>Number of visits in trial per patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Colectomies at Week 48</measure>
    <time_frame>Week 48</time_frame>
    <description>Proportion of patients with colectomy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>UC related Hospitalizations at Week 48</measure>
    <time_frame>Week 48</time_frame>
    <description>Proportion of UC related hospitalizations</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">238</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Group Standard of care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In standard of care, patient only visits every 3 months the doctor so the optimization of treatment can be done only at this frequency.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Groupe T2T with telemonitoring and patient education</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment with e-Monitoring, home fecal calprotectin testing and therapy education.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adalimumab</intervention_name>
    <description>Patients will all receive Adalimumab 160/80/40mg EOW until V1 (W14) followed by 40mg EOW until V2 (W26)</description>
    <arm_group_label>Group Standard of care</arm_group_label>
    <arm_group_label>Groupe T2T with telemonitoring and patient education</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Calprotectin</intervention_name>
    <description>Fecal calprotectin dosing at home with IBDoc</description>
    <arm_group_label>Groupe T2T with telemonitoring and patient education</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>e-Monitoring</intervention_name>
    <description>e-Monitoring at Week 6, Week 10, Week 14, Week 18, Week 22, Week 26, Week 34, Week 38, Week 42 and Week 48&#xD;
The patient must complete the first 2 questions of the Mayo score:&#xD;
Stool frequency&#xD;
The frequency of bleeding&#xD;
He must also complete the information on his injections</description>
    <arm_group_label>Groupe T2T with telemonitoring and patient education</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Therapy Education</intervention_name>
    <description>Patient Education at W0, W2, W14, W26 and W38.</description>
    <arm_group_label>Groupe T2T with telemonitoring and patient education</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults with moderately-to-severely active Ulcerative Colitis (UC) who had an&#xD;
             inadequate response to or failed to tolerate steroids and thiopurines (azathioprine or&#xD;
             6-mercaptopurine) or methotrexate or adults with moderately-to-severely active UC who&#xD;
             had no response to an adequate steroid course&#xD;
&#xD;
          -  Age ≥ 18 years and &lt; 75 years&#xD;
&#xD;
          -  Patients scheduled to start a treatment with adalimumab&#xD;
&#xD;
          -  Naïve to anti-TNF therapy and other biologics (i.e anti-integrin antibodies) or other&#xD;
             biologics known to be effective for UC (approved or investigational)&#xD;
&#xD;
          -  Naïve to JAK inhibitors (approved or investigational)&#xD;
&#xD;
          -  Adults with moderately-to-severely active UC for at least 3 months with a Mayo score&#xD;
             of 6-12 points (endoscopy subscore of at least 2)&#xD;
&#xD;
          -  Established diagnosis of UC for at least 3 months (pancolitis, left-sided colitis,&#xD;
             proctosigmoiditis and proctitis are allowed).&#xD;
&#xD;
          -  Patient has to be treated with oral 5-ASA at time of inclusion regardless of the dose&#xD;
             if no contra-indication.&#xD;
&#xD;
          -  Azathioprine, 6-mercaptopurine or methotrexate will be stopped two weeks before&#xD;
             inclusion.&#xD;
&#xD;
          -  A contraceptive method during the whole trial for childbearing potential female&#xD;
&#xD;
          -  Patient familiar with Smartphone and internet use&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The patients should not present any of the following criteria:&#xD;
&#xD;
          -  People unable to give their consent (because of their physical or mental state).&#xD;
&#xD;
          -  Absence of written consent.&#xD;
&#xD;
          -  Pregnancy or breastfeeding.&#xD;
&#xD;
          -  Patients with severe acute colitis or patients at imminent risk for colectomy.&#xD;
&#xD;
          -  History of colectomy.&#xD;
&#xD;
          -  History of colonic mucosal dysplasia or adenomatous colonic polyps that are not&#xD;
             removed.&#xD;
&#xD;
          -  Screening stool trial positive for enteric pathogens or Clostridium difficile toxin.&#xD;
&#xD;
          -  Oral corticosteroids at a dose &gt; 40 mg prednisone or its equivalent per day at&#xD;
             inclusion (oral steroids should be at stable dose at least 7 days before inclusion)&#xD;
&#xD;
          -  Any current or previous use of cyclosporine, tacrolimus, anti-TNF therapy, and other&#xD;
             biologics, including anti-integrin antibodies (approved or investigational), JAK&#xD;
             inhibitors (approved or investigational), or any current or previous use of an&#xD;
             investigational agent within 5 half-lives of that agent before the first trial agent&#xD;
             injection.&#xD;
&#xD;
          -  Contraindication to anti-TNF therapy including:&#xD;
&#xD;
               -  Active infection.&#xD;
&#xD;
               -  Non-treated latent tuberculosis.&#xD;
&#xD;
               -  Heart failure (NYHA: Grade III and IV).&#xD;
&#xD;
               -  Malignancy during the previous 5 years.&#xD;
&#xD;
               -  Demyelinating neurological disease.&#xD;
&#xD;
               -  Current or recent (less than 4 weeks) vaccination with attenuated live vaccines&#xD;
&#xD;
          -  Patients with a dominant arm deficiency or physical impairment impeding the&#xD;
             achievement of the tests&#xD;
&#xD;
          -  Patients using a prohibited medication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xavier Hebuterne, MD PhD</last_name>
    <phone>04 92 03 65 75</phone>
    <email>hebuterne.x@chu-nice.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre hospitalier de Cholet</name>
      <address>
        <city>Cholet</city>
        <state>Maine Et Loire</state>
        <zip>49300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Amiens- Picardie (site Sud)</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathurin Fumery</last_name>
      <email>fumery.mathurin@chu-amiens.fr</email>
    </contact>
    <investigator>
      <last_name>Mathurin Fumery</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Caen Hôpital Côte de Nacre</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>CHU Estaing</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>APHP - Hôpital Beaujon</name>
      <address>
        <city>Clichy</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yoram Bouhnik</last_name>
      <email>yoram.bouhnik@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Yoram Bouhnik</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Colmar - Hôpital Pasteur</name>
      <address>
        <city>Colmar</city>
        <zip>68024</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniel BENITAH</last_name>
      <email>daniel.benitah@ch-colmar.fr</email>
    </contact>
    <investigator>
      <last_name>Daniel BENITAH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Lille Hôpital Claude Huriez</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Nachury</last_name>
      <email>maria.nachury@CHRU-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Maria Nachury</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHM - Hôpital Nord</name>
      <address>
        <city>Marseille</city>
        <zip>13915</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mélanie Serrero</last_name>
      <email>MELANIE.SERRERO@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Mélanie Serrero</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GHI Le Raincy-Montfermeil</name>
      <address>
        <city>Montfermeil</city>
        <zip>93370</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphane Nahon</last_name>
      <email>snahon@ch-montfermeil.fr</email>
    </contact>
    <investigator>
      <last_name>Stéphane Nahon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier - Hôpital Saint Eloi</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucile Boivineau</last_name>
      <email>l-boivineau@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Lucile Boivineau</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nantes - Hôpital Hotel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Trang</last_name>
      <email>caroline.trang@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Caroline Trang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nice- Hopital l'Archet</name>
      <address>
        <city>Nice</city>
        <zip>62002</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier Hebuterne</last_name>
      <email>hebuterne.x@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>Xavier Hebuterne</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu nimes - Hôpital Universitaire Caremeau</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ludovic Caillo</last_name>
      <email>ludovic.caillo@chu-nimes.fr</email>
    </contact>
    <investigator>
      <last_name>Ludovic Caillo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux - Hôpital Haut Lévêque</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Rennes Hôpital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CH Saint Etienne Hopital Nord</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xavier Roblin</last_name>
      <email>xavier.roblin@chu-st-etienne.fr</email>
    </contact>
    <investigator>
      <last_name>Xavier Roblin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Toulon - CHITS CH Sainte Musse</name>
      <address>
        <city>Toulon</city>
        <zip>83056</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse - Hôpital Rangueil</name>
      <address>
        <city>Toulouse</city>
        <zip>31403</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cyrielle Gilletta</last_name>
      <email>gilletta.c@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Cyrielle Gilletta</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Tourcoing - Hôpital Gustave Dron</name>
      <address>
        <city>Tourcoing</city>
        <zip>59200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Noemie Tavernier</last_name>
      <email>ntavernier@ch-tourcoing.fr</email>
    </contact>
    <investigator>
      <last_name>Noemie Tavernier</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nancy - Hôpital de Brabois</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Franck CARBONNEL</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <state>Île-de-France</state>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Franck CARBONNEL, MD</last_name>
      <email>franck.carbonnel@bct.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Franck CARBONNEL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>October 28, 2019</study_first_submitted>
  <study_first_submitted_qc>November 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2019</study_first_posted>
  <last_update_submitted>June 28, 2021</last_update_submitted>
  <last_update_submitted_qc>June 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IBD</keyword>
  <keyword>UC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

